Plasma Galectin-3 and urine proteomics predict FEV1 improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study

A Riccio(University of Palermo), Giorgio Walter Canonica(Humanitas University), Fabiana Saccheri(Novartis (Italy)), Rossana Rossi(University of Parma), Pierluigi Mauri(Institute of Biomedical Technologies), Marta Bartezaghi(Novartis (Italy)), Laura De Ferrari(Istituti di Ricovero e Cura a Carattere Scientifico), Dario Di Silvestre(Institute of Biomedical Technologies)
World Allergy Organization Journal
January 1, 2020
10.1016/j.waojou.2019.100095
Cited by 23

Related Papers

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k